Lesser Highlights CTs Generic GLP-1 Legislation at National Conference Today, State Senator Matt Lesser , Senate Chair of the Human Services Committee, spoke at the National Academy for State Health Policy (NASHP) Annual Health Policy Conference in San Diego on Connecticuts recently enacted bipartisan prescription drug law, which puts Connecticut in the front of the pack of states in controlling drug costs
India Demonstrates Strong Market Potential with Rising Obesity Prevalence Revenue from obesity GLP-1 treatment in India is expanding at a CAGR of 28.4%, supported by increasing obesity rates in metropolitan areas and growing awareness of cardiovascular risk factors
Mechanism gaps Despite four decades of research, DSIP precise mechanism of action remains unclear
Improper storage can render the water unusable and potentially hazardous for medical applications
AOD-9604 peptide may help you feel satiated longer after eating and decrease your appetite, so you consume fewer calories
Off-Label Popularity Although not FDA-approved for weight loss under the Ozempic label, semaglutide's active ingredient is marketed under another brand, Wegovy, specifically for obesity management
